Epcoritamab for B-cell lymphoma after CAR-T therapy
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a type of B-cell lymphoma (like diffuse large B-cell lymphoma) that tested positive for CD20 within the last 6 months.
- You must have received one of three specific CAR-T cell therapies (axicabtagene ciloleucel, tisagenlecleucel, or lisocabtagene maraleucel) and had only a partial response at day 30.
- You must have measurable disease that can be seen on a PET-CT scan.
- Your overall health must be good enough to carry out daily activities (ECOG score 0, 1, or 2).
- Your blood counts and organ function (kidney, liver, heart) must meet minimum levels as tested within 14 days before enrolling.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
This trial tests whether a drug called emapalumab can reduce serious side effects from CAR-T cell therapy, a treatment for large B-cell lymphoma that has come back or not responded to earlier treatments. If you qualify, you would receive emapalumab alongside your CAR-T treatment to help make it safer.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
This trial tests a combination of two immune therapies—epcoritamab (a bispecific antibody) and CAR T cells—for people with large B-cell lymphoma whose cancer didn't respond to first treatment. The goal is to see if this combination works better than CAR T cells alone.
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
This study tests a new drug combination (epcoritamab and lenalidomide) for people whose large B-cell lymphoma has not responded to or returned after CAR T-cell therapy. The goal is to see if this combination can help control the lymphoma and improve outcomes.
Hear when a new Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.